RxDoctor Payments Data

Gary Toppin, PA

Medical · Rocky Mount, NCNPI 1528328572

Payments from drug & device makers

$5,793in general payments, 2019–2025

Across 398 payments — averaging $14.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$725
  • AstraZeneca$620
  • Pfizer$386
  • GSK$342
  • Lilly USA, LLC$269
  • plus $2K from 41 others

What the payments were for

  • Food & beverage$5,793100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,793 in reported general payments places this provider in the 90th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$72,276
Medicare patients
231
Services billed
2,777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide114$172,666
FarxigaDapagliflozin Propanediol45$60,509
Trelegy ElliptaFluticasone/Umeclidin/Vilanter32$33,571
RybelsusSemaglutide17$31,590
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog17$26,613
XareltoRivaroxaban26$23,486
JanuviaSitagliptin Phosphate13$19,213
EliquisApixaban15$18,978
JardianceEmpagliflozin12$11,550
Synjardy XrEmpagliflozin/Metformin Hcl11$9,870
Breo ElliptaFluticasone/Vilanterol12$5,375
SymbicortBudesonide/Formoterol Fumarate12$4,290
Levothyroxine Sodium184$3,635
Olmesartan Medoxomil160$3,620
Atorvastatin Calcium318$2,843

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$725$204,257131 claims
AstraZenecaFarxiga, Symbicort$620$64,79957 claims
GSKTrelegy Ellipta, Breo Ellipta$342$38,94644 claims
Johnson & JohnsonXarelto$60$23,48626 claims
Boehringer IngelheimJardiance, Synjardy Xr$173$21,41923 claims
MerckJanuvia$141$19,21313 claims
PfizerEliquis$386$18,97815 claims
AbbVieSynthroid$1,225$1,46726 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 878 medical providers in North Carolina.

Other medical in Rocky Mount

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →